
    
      Combinations of durvalumab and tremelimumab have also been studied. While the combination has
      been studied in over 200 people, it is not clear if it can offer better results when it is
      combined with chemotherapy.

      Recently, immunotherapies that target the PD-1/PD-L1 axis have shown promise in treating
      patients with non-small cell lung cancer.
    
  